



(51) International Patent Classification:

A61K 47/02 (2006.01) A61P 15/18 (2006.01)
A61F 6/14 (2006.01)

(21) International Application Number:

PCT/FI2013/050068

(22) International Filing Date:

22 January 2013 (22.01.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20125069 23 January 2012 (23.01.2012) FI

(71) Applicant: BAYER OY [FI/FI]; Pansiontie 47, FI-20210
Turku (FI).

(72) Inventors: LYYTIKÄINEN, Heikki; Onkitie 2, FI-21100
Naantali (FI). JUKARAINEN, Harri; Vadelmakatu 3, FI-
21620 Kuusisto (FI).

(74) Agent: OY JALO ANT-WUORINEN AB; Iso Roob-
ertinkatu 4-6 A, FI-00120 Helsinki (FI).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).


Published:

— with international search report (Art. 21(3))

[Continued on next page]

(54) Title: A DRUG DELIVERY SYSTEM

Fig. 1



(57) Abstract: The present invention
provides a novel drug delivery system
for the controlled release of therapeutic-
ally active substances at a predeter-
mined, essentially constant release rate
over a prolonged period of time. The de-
livery system comprises at least one core
comprising said therapeutically active
substance(s), at least one membrane en-
casing the core and an intermediary layer
of a substantially inert material, wherein
the intermediary layer is applied between
the core and the membrane or between
two membrane layers.



-
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*